Every little helps. A new ruling on the patents for Shire's top-selling drug Vyvanse will help bolster the company's case that AbbVie's recent takeover offer undervalues the firm.
Every little helps. A new ruling on the patents for Shire's top-selling drug Vyvanse will help bolster the company's case that AbbVie's recent takeover offer undervalues the firm.
A US district court judge has ruled that 18 patent claims from four FDA Orange Book-listed patents on the ADHD...
Create an account to read this article
Already a subscriber?
Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
Chiesi and the Boston-area biotech will co-develop a CRISPR-Cas gene-editing therapy for primary hyperoxaluria type 1. They hope to provide a curative therapy for the rare disease.
Plus deals involving Klotho/Turn, BioLineRx/Hemispherian, Dogwood/Serpin, Harrow/Melt, Gossamer/Respira, Lilly/Prellis, BI/TegMine and more.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.
Restructuring Edition: Takeda’s shift away from cell therapies will impact 137 employees. Meanwhile, Bolt is cutting its workforce by 50% to extend its cash runway into 2027, Innate’s staffing will drop by 30% and X4 will halve its workforce under a restructuring plan.
